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Introduction: The Myasthenia Gravis-Activities of Daily Living scale (MG-ADL) is a short, and
easy to use disease-speciﬁc quality of life during daily routine tool in myasthenia gravis.
Objectives: The purpose of our work was to evaluate neurological condition patients with
myasthenia gravis using the form MG-ADL in order to enable the introduction in common
use of an instrument which allows for the assessment of patients with myasthenia gravis.
Patients and Methods: The total number of 50 patients with MG were qualiﬁed for the
examination. Each patient underwent neurological examination and completed the quality
of life evaluation questionnaire MQ-ADL. Additionally, each patient was asked to evaluate
the quality of his/her life by means of questionnaire MG-QOL 15 and MG Composite in Polish
language version.
Results: Our analysis showed a positive correlation with other scales used - MG-QOL 15,
MGFA, MG Composite. The intensiﬁcation of neurological symptoms showed signiﬁcant
relation with obtained higher number of points in MG-ADL questionnaire. The MG-ADL was
found to have high internal consistency, test–retest reliability, and concurrent validity.
Conclusion: We conﬁrmed reliability and dependability of the questionnaire in the the test-
retest assessment. The MG-ADL is accepted to be a reliable and valuable tool for measuring
disease-speciﬁc QOL in Polish patients with MG.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Myasthenia gravis (MG) is a complex nervous system disease;
more precisely, it concerns the neuromuscular junction, and* Corresponding author at: Department of Neurology, Medical Univers
E-mail address: irozmilowska@gmail.com (I.M. Rozmilowska).
https://doi.org/10.1016/j.pjnns.2017.12.012
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sits pathomechanism has auto-immunological background. It is
characterized by extensive muscular fatigue. The unnatural
weakness of muscle strength occurring in myasthenia presents
variable intensiﬁcation [1]. The epidemiological examinations
showed that the disease occurs with frequency of 10–15 personsity of Silesia, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.
p. z o.o. All rights reserved.
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on marking the level of antibodies anti-AChR, which occur at
85% patients. The remaining 15% described as seronegative
may have other types of antibodies, such as against muscle-
speciﬁc tyrosine kinase (anti-MuSK) or anti-titin antibodies. The
patients with diagnosed myasthenia are characterized by a
signiﬁcant variability of the course of their disease [2,3].
For doctors, the grounds for assessment of the patient's
clinical condition are the occurring neurological symptoms
and their evolution observed by the patient himself. The
treatment process is difﬁcult and the therapy should be
precisely adjusted to the existing symptoms. Thus, the point of
reference in the assessment of patients are observations
performed during the patient's successive appointments. One
of the instruments used to assess patients with myasthenia
gravis is the Myasthenia Gravis-speciﬁc Activities of Daily Living
scale (MG-ADL). This scale was developed in the 1990s by Wolfe
Gil. It is an easy to use, 8-item questionnaire, which may be
completed both by the doctor and the patient himself [4].
The purpose of our work was to evaluate neurological
condition of myasthenia gravis patients using the MG-ADL
form, in order to validate the tool and enable its introduction
for daily use in the assessment of patients suffering from
myasthenia gravis.
2. Materials and methods
2.1. Patients and material
The examination was carried out in the Department of
Neurology at Medical University in years 2015–2016. The
uniform criteria of inclusion in the examination covered: (1)Table 1 – MG-ADL questionnaire in the Polish language version
gravis).
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grounds of clinical criteria, serological and electro-stimulating
tests, (2) over 18 years of age, (3) the minimum duration of the
disease 6 months. The patients were subjected to neurological
examination, they underwent detailed interviews and on the
grounds of the obtained information, a doctor completed an
MG-ADL questionnaire. Relatively small study sample was the
limitation of the study.
2.2. The Myasthenia Gravis-speciﬁc Activities of Daily
Living questionnaire
The Myasthenia Gravis-speciﬁc Activities of Daily Living
scale consists of the assessment of 8 parameters: speaking,
chewing, swallowing, breathing, self-care activities (brushing
the teeth or combing the hair), simple physical activities
(getting up from a chair), double vision and eye lid dropping.
Each parameter is subjected to assessment depending on the
degree of symptoms intensiﬁcation, awarding points from 0 to
3 points. The maximum number a patient may receive is
24 points. The higher the score of points, the bigger limitations
of the patient in everyday life activities caused by intensiﬁca-
tion of myasthenia gravis [4,5]. Table 1 presents the Polish
version of the questionnaire The Myasthenia Gravis-speciﬁc
Activities of Daily Living.
Each patient was assessed twice to conﬁrm the scale
reliability (test–retest) – the second assessment was conducted
during the follow-up after 4 weeks from the ﬁrst meeting.
Additionally, the classiﬁcation of patients into adequate MGFA
classes (Myasthenia Gravis Foundation of America clinical
classiﬁcation) was made on the grounds of their neurological
examination and in conformity with MG Composite scale
(Myasthenia Gravis Composite) [6,7]. The above scales were. MG-ADL (Ocena czynności dnia codziennego w miastenii
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Table 2 – Demographic and clinical characteristics of
patients enrolled into the study.
Patients (n) 50
Myasthenia character
Ocular (%) 48
Generalized (%) 52
Mean age of patients (years) 60.66
Range age (years) 30–81
Mean duration of disease (years) 9.48
Range of disease (years) 0.5–34
Gender
Female (%) 56
Male (%) 44
Mean antibodies against rec. Ach (nmol/l) 8.93
Range antibodies against rec. Ach (nmol/l) 0.1–85
Treatment (%)
Anticholinesterase drugs 98
Steroids 16
Azathioprine 6
Classiﬁcation of MGFA (%)
MGFA 0 22
MGFA I 38
MGFA II a 16
MGFA II b 4
MGFA III a 12
MGFA III b 2
MGFA IV a 4
MGFA IV b 2
MGFA V 0
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of ‘‘severity’’ of the disease. Each patient also ﬁlled in the
MG-QOL 15 (Myasthenia Gravis – quality of life 15) form [8].
2.3. Ethics
The work described in this article has been carried out in
accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans Nr KNW/0022/KB1/68/15; uniform requirements
for manuscripts submitted to biomedical journals. Each
patient expressed a written consent for participation in the
test. Before starting the study, we had received a written
consent from the author of the scale regarding the perfor-
mance of the test.
2.4. Statistical analysis
The basic statistical analysis included elements of descriptive
statistics such as average, median, standard deviation,
percentage distribution and variance. The analysis of correla-
tion between MG-ADL, MG-QOL 15 and MG Composite was
performed. For this purpose, both Pearson's coefﬁcient and
Spearman's coefﬁcient were used. Receiver operating charac-
teristic (ROC) curve and sensitivity/speciﬁcity analyses were
conducted based on the physician's impression of change
according to cutoffs. The reliability of this method was
conﬁrmed in the test–retest reliability. The correlations
obtained in all cases were almost equal. The study of results
was conducted on the grounds of statistical analysis using
STATISTICA v 12 PL and EXCEL programmes.
3. Results
50 patients were qualiﬁed for the test. The patients with ocular
myasthenia gravis constituted 48%, and generalized MG – 52%.
The average age of the patients was 60.6 years, the average
duration of the disease was 9.5 years, and 56% of patients were
women. A total of 86% of patients were acetylcholine receptor
antibody positive (AChR+) – with 8.93 nmo/l on average; at 56%
of patients persistent thymus was diagnosed during the
diagnosis, and thymoma at 10%. The division of patients
according to MGFA classiﬁcation was distributed in the
following way: 38% class I, 16% class II a, class II b 4%, in
class III a 12% and III b 2%, class IV a and 4, whereas class IV b
2%. There were 22% in the remission state, i.e. class 0 none of
the examined persons was intubated and (class V). Analysing
the applied treatment, 98% of patients took acetylcholinester-
ase inhibitors, 16% additionally used steroid therapy, and 6% –
azathioprine.
The results of analysis of basic descriptive statistic, taking
into account the division of patients according to selected
criteria, are presented in Table 2.
Pearson's and Sperman's correlation between MG-ADL,
MG-QOL 15, MG Composite and MGFA was conducted. The
comparison of results of MG-ADL questionnaire showed a
positive correlation with all results of questionnaires, respec-
tively MG-ADL vs MG-QOL 15 r = 0.85 points, MG-ADL vs MGFA
r = 0.80 points and MG-ADL vs MG Composite r = 0.96 point.These are statistically signiﬁcant results at the level of
p < 0.001, showing large correlation of coefﬁcients, remarkably
marked with reference to MG Composite scale. The presented
correlations are shown in Figs. 1–3.
For the purpose of the study, the assessment of patients'
clinical condition using MGFA classiﬁcation was assumed as
the so-called ‘‘golden standard’’. The patients qualiﬁed in
neurological assessment for MGFA 0 – MGFA IIb groups were in
the state of remission or they had intensiﬁed symptoms poorly
diagnosed. The patients qualiﬁed for MGFA IIIa – MGFA V
classes were those who revealed moderate or intensiﬁed
image of symptoms in clinical examination. Sensitivity and
speciﬁcity of MG-ADL classiﬁcation were assessed. In our
study, a few points of MG-ADL cutoff points were determined,
which were later compared with the patients' neurological
condition. The result of 10 points enabled the qualiﬁcation of
90% of patients, according to a determined scheme, and the
assessment according to MG-ADL scale was adequate to
patients' neurological condition in conformity with MGFA
classiﬁcation. ROC curve analysis conﬁrmed very good
differentiating properties of MG-ADL (ﬁeld below the curve
pod 0.91; p < 0.001). Fig. 4 shows ROC curve for MG-ADL.
Another assessment of all patients was performed accord-
ing to MG-ADL questionnaire after 4 weeks from the ﬁrst visit.
The average MG-ADL score at the ﬁrst visit was 4.02, the
median was 3.0, min. value 0.0, max value 17.0, the lower
quartile equalled 1.0, the upper quartile – 5.0, and the standard
deviation was 3.97. The MG-ADL results did not differ by more
than 2 points between the assessments. The test–retest
reliability coefﬁcient was 92%, with a lower 94% conﬁdence
interval [CI] of 88%, indicating excellent test–retest reliability.
The differences in assessment of particular test elements were
Fig. 2 – Correlation diagram questionnaire MG-ADL with MG Composite scale. (MG-ADL – Myasthenia Gravis-specific
Activities of Daily Living scale; MGC – Myasthenia Gravis Composite).
Fig. 1 – Correlation diagram questionnaire MG-ADL with MG-QOL 15 scale. (MG-ADL – Myasthenia Gravis-specific Activities of
Daily Living scale; MG-QOL 15 – Myasthenia Gravis – quality of life 15).
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double vision (7/50).
4. Discussion
Our observations conﬁrmed MG-ADL questionnaire as a useful
tool for assessment of everyday life functioning of Polish
population patients with diagnosed myasthenia gravis taking
neurological symptoms of the disease into consideration.
Analysis showed a positive correlation with other scales used –
MG-QOL 15, MGFA, MG Composite. The intensiﬁcation of
neurological symptoms (MGFA II b, MGFA III b and MGFA IV b),
and in particular the presence of symptoms other than eye
symptoms, showed signiﬁcant relation with obtained higher
number of points in MG-ADL questionnaire. The test–retest
assessment conﬁrmed reliability and dependability of thequestionnaire, no statistically signiﬁcant differences were
determined for measurements conducted twice in a speciﬁc
time interval. The obtained variability by over 2 points in two
examined aspects (eye lid dropping and double vision) may be
explained with signiﬁcant ﬂuctuation of apocamnosis symp-
toms over a short period of time (e.g. during a day). The
conﬁrmation of good sensitivity and speciﬁcity is ROC curve,
and the differentiating properties of MG-ADL questionnaire
were conﬁrmed in other previous studies.
There are certain limitations in our research. Firstly, the
most important is the number of persons included in the
research. We are aware that the reliability of research is
connected with the number of patients subject to assessment,
and thus, we are continuously expanding our group by
examining new patients with diagnosed MG. The second
important matter is the difﬁculty in determining correct points
of reference. The MG-ADL scale is also the scale in which a
Fig. 4 – Receiver operating characteristic (ROC) curve of MG-
ADL. (MG-ADL – Myasthenia Gravis-specific Activities of
Daily Living scale).
Fig. 3 – Correlation diagram questionnaire MG-ADL with neurological scale MGFA. (MG-ADL – Myasthenia Gravis-specific
Activities of Daily Living scale; MGFA – Myasthenia Gravis Foundation of America clinical classification remission – 1; MGFA I
– 2; MGFA IIa – 3; MGFA IIb – 4; MGFA IIIa – 5; MGFA IIIb – 6; MGFA IVa – 7; MGFA IVb – 8; MGFA V – 9).
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inﬂuence on everyday life, at the same time referring to
existing clinical symptoms. It is difﬁcult to clearly indicate
which point value may indicate remission. Some patients in
our study had a value of 0.0, which corresponded to an MGFA
score. Patients who received 1.0 pts complained of occasional
discomfort, which may also occur in patients with remission.
Scores 2 and above in our opinion appear to be found in
patients who, according to the MGFA classiﬁcation, presented
signs of myasthenia gravis. We used three other scales for our
analysis, which reﬂected both the aspect of the patient's
subjective feelings as well as objective neurological examina-
tion. The third important issue is, regardless of our analysis,
but concerning the questionnaire itself, particular examinedaspects – they are not equivalent. In the case where a patient
receives the highest number of points (3 points) regarding
respiratory disorders, it is the patient who needs mechanical
ventilation. However, if he/she receives 3 points for permanent
double vision or diplopia, his/her clinical condition may
signiﬁcantly differ from another patient with a similar total
number of points. Thus, from a doctor's point of view, it is
important and expedient to use MG-ADL scale as one of the
parameters for assessment of a patient with myasthenia
gravis.
Previous research suggests that assessment according to
MG-ADL questionnaire may be the ﬁnal stage of conducted
observations in clinical examinations. A signiﬁcant advantage
of the questionnaire is its simplicity and the fact that it can be
completed by a patient alone, without the doctor's participa-
tion.
MG-ADL scale was used as the ﬁnal stage in recently
completed research by Bourgue et al. it was a retrospective
cohort study conducted in a hospital in Canada, the purpose of
which was the assessment of efﬁciency of subcutaneous
application of immunoglobulin in the course of myasthenia
gravis. Statistically signiﬁcant improvements were documen-
ted in the MG-ADL, MG-QOL and VAS scales [9]. Other pilot
study assessing the inﬂuence of leﬂunomide treatment on the
course of myasthenia gravis was conducted by Chen et al. In
that project, MG-ADL questionnaire was also used as one of
the ﬁnal points, presenting a reliable insight into improvement
or lack of improvement in case of the applied procedures [10].
Analysing other clinical research, it can be noted that MG-ADL
questionnaire is used in the majority of studies concerning
new forms of myasthenia gravis treatment, similarly to other
projects concerning, among others, a therapy with metho-
trexate or tacrolimus. The study conducted by Zhao et al.
showed the decrease of neurological symptoms, especially in
patients with generalized form. The following scales were
used as ﬁnal points: MG-ADL, MMT (manual muscle testing),
MGFA, which in joint analysis demonstrated large precision of
measurements [11].
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In his research, he analyzed the inﬂuence of smoking
cigarettes on the quality of life of patients with the ocular
form of myasthenia gravis. The basic tool used to conduct the
observations was the MG-ADL form, application of which
enabled the patient to assess the occurring changes. The
research results suggest that quitting smoking may have
beneﬁcial inﬂuence on symptoms reduction [12].
The course of myasthenia gravis is very variable in many
patients. Clinical assessment of the treatment's effectiveness
may be easier using scales specially designed for this purpose.
In addition to the MG-ADL scale, it is worth noting the MG-
Composite and MG-QOL 15 scale. The ﬁrst one allows for
relative objectivity of the patient's condition based on
neurological examination. The second is an exponent of the
functioning of patients and the assessment of psychosocial
aspects. These observations have been included in many
studies.
In recent years, the authors of the scale Wolfe G. together
with Muppidi et al. conducted a multi-centre analysis of MG-
ADL scale use with its validation. In their assessment, the
reference point were scales MG-QOL 15 and MG-Composite. 87
patients were examined and the obtained results conﬁrmed a
high level of correlation between the instruments used. The
test conﬁrmed that the MG-ADL is useful as a research tool as
well as in routine clinical management [5].
5. Conclusion
To sum up the above considerations, it is worth remembering
the holistic assessment of patients. Myasthenia gravis with its
speciﬁc symptoms often demonstrates signiﬁcant inﬂuence
on everyday life activities of the patients. Frequently, they
cannot perform basic tasks such as washing themselves,
driving a car or eating. Thus, therapeutic actions should
aim at possibly signiﬁcant reduction of symptoms visible
in the patients' neurological condition improvement, but, at
the same time, it should lead to improving the quality of life,
which is evaluated by the patient himself.
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